NCT01467531View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Infections, Human Immunodeficiency Virus and Hepatitis
Interventions
DRUG

Dolutegravir

50mg q 24h

DRUG

Rlipivirine

25mg q24h

DRUG

GSK1265744

30mg q24h

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

Shionogi
All Listed Sponsors
collaborator

Shionogi

INDUSTRY

lead

ViiV Healthcare

INDUSTRY